Lucena González, María Isabel

Coinvestigador Responsable en Hepatogastroenterología, Farmacología y Terapéutica Clínica Traslacional

Coinvestigador Responsable en Hepatogastroenterology, Pharmacology, and Translational Clinical Therapeutics.


  • Professor of Pharmacology at the University of Malaga
  • Director of the Clinical Pharmacology Service at the University Hospital of Malaga. Coordinate the Unit of Clinical Reseach and Clinical Trials (UICEC-IBIMA) ascribed to the Central Platform SCReN
  • Founding Director of IBIMA (Malaga Health Research Institute) (2013-2017).
  • She belongs to CIBERehd group on DILI granted by the Spanish Ministry of Health and to the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).
  • Expert of the AEMPS and the European Medicines Agency for the evaluation of liver safety of drugs. Director of the PAIDI Group CTS 649
  • Member of the Executive Committee of the International Union of Basic and Clinical Pharmacology.
  • Rapporteur of CIOMS working Group on Drug-Induced Liver Injury (DILI). Member of the expert panel of the European Association for the Study of the Liver Clinical Practice Guidelines on Occupational Liver Diseases.
  • Funder and coordinator of the Spanish DILI Registry (www.spanishdili.uma.es) and of the Spanish Latin-American DILI Network and the recently set-up Prospective European DILI Registry awarded by EASL.
  • Scientific coordinator of the Cost Action 17112 Pro Euro DILI NET (https://proeurodilinet.eu/). Partner of the IMI TRANSBIOLINE Project 2018
  • The main lines of research in DILI are pharmacoepidemiology, identification of risk factors and patient stratification, genetic, OMIC and immunophenotyping studies in order to improve the mechanistic understanding of DILI and the qualification of novel biomarkers and their transfer into clinical practice.
  • H-index: 41. 10 publications were cited more than 100 times.

Contacto con Investigador

Proyectos Activos

  • 2017
    INSTITUTO DE SALUD CARLOS III RETIC

    PT17/0017/0020 PLATAFORMA DE UNIDADES DE INVESTIGACION CLINICA Y ENSAYOS CLINICOS

    01/01/2018 31/12/2020
    IP
  • 2016
    INSTITUTO DE SALUD CARLOS III PI

    PI16/01748 Análisis de la respuesta inmunitaria adaptativa y los receptores implicados en el immune check point en el desarrollo y gravedad de la hepatotoxicidad. Influencia de la microbiota intestinal

    01/01/2017 31/12/2019
    IP
  • 2016
    CONSEJERÍA DE SALUD PI

    PI-0274-2016 Identificación de Biomarcadores Diagnósticos y Pronósticos en Hepatotoxicidad. Estudio Comparativo Con Controles Sanos y Hepatitis Aguda de Diferente Etiología

    21/12/2016 20/12/2019
    Colaborador

Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263